In a report published Friday, Morgan Stanley analyst Ricky R. Goldwasser reiterated an Overweight rating and $19.00 price target on Albany Molecular Research AMRI.
In the report, Morgan Stanley noted, "With uncertainty about 2015 guidance now resolved, investor focus should now shift to execution in 2015, with key value drivers being potential for margin expansion in thecore business and executing on M&A strategy."
Albany Molecular Research closed on Thursday at $17.22.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in